The US Food and Drug Administration on 2 August approved Coherus BioSciences, Inc.’s Cimerli (ranibizumab-eqrn) as the first interchangeable biosimilar to Genentech, Inc.’s age-related macular degeneration treatment Lucentis, without the need for a “switching” study.
Cimerli is approved for all five of Lucentis’ indications: neovascular (wet) AMD; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy; and myopic choroidal neovascularization (CNV). It is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?